Ginkgo Bioworks, Inc. ("Ginkgo"), the organism company, announced it has signed a purchase agreement to acquire Dutch DNA Biotech B.V. ("Dutch DNA"), a company based in Utrecht, Netherlands with a proprietary platform technology focused on the development of fungal strains and fermentation processes for the production of proteins and organic acids. With this acquisition, Ginkgo will, for the first time, expand Ginkgo operations internationally. The acquisition is expected to close in July 2021.
This news follows a period of momentum and growth for Ginkgo. On 11 May 2021, Ginkgo announced it has agreed to a business combination with Soaring Eagle Acquisition Corp. (Nasdaq: SRNG), a publicly traded special purpose acquisition company, that will result in Ginkgo becoming a publicly-listed company. The transaction implies a pre-money equity valuation for Ginkgo of $15.0 billion, and is expected to provide up to $2.5 billion of gross cash proceeds.
The core deal team consisted of Jeanine Evertse, Isabelle Wilcke, Eline van Marle, Mariebelle Timmermans, Rebecca Runa Pinto – Noome and Ruud Smits (Corporate M&A), Aira Scheijvens, Josephine de Graaf (Corporate M&A Notarial), Nina Kielman, Alissia Sudibyo (Tax).